Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of CD30 targeting in malignant lymphoma.

Literature DB >> 24570331

Role of CD30 targeting in malignant lymphoma.

Abstract

CD30 is an important therapeutic target for the treatment of malignant lymphomas. CD30 is a member of the TNF cell receptor superfamily and is highly expressed in a variety of lymphoma subsets, including Hodgkin lymphoma and anaplastic large cell lymphoma. Initial studies evaluated the safety and efficacy of several monoclonal antibodies targeting CD30, with limited success. More recently, the anti-CD30 drug-conjugate brentuximab vedotin produced high response rates with an excellent safety profile. These results lead to the approval of brentuximab vedotin for the treatment of patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. Current studies are focusing on incorporating brentuximab vedotin in front-line regimens and expanding its potential clinical utility in other CD30-expressing malignancies.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24570331 DOI： 10.1007/s11864-014-0275-7

Source DB: PubMed Journal: Curr Treat Options Oncol ISSN： 1534-6277

50 in total

1. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.

Authors: C Kurts; F R Carbone; M F Krummel; K M Koch; J F Miller; W R Heath
Journal: Nature Date: 1999-03-25 Impact factor: 49.962

2. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory.

Authors: Fabrina M C Gaspal; Mi-Yeon Kim; Fiona M McConnell; Chandra Raykundalia; Vasilios Bekiaris; Peter J L Lane
Journal: J Immunol Date: 2005-04-01 Impact factor: 5.422

3. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

Authors: H J Gruss; N Boiani; D E Williams; R J Armitage; C A Smith; R G Goodwin
Journal: Blood Date: 1994-04-15 Impact factor: 22.113

4. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.

Authors: S S Mir; B W Richter; C S Duckett
Journal: Blood Date: 2000-12-15 Impact factor: 22.113

5. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival.

Authors: C S Duckett; C B Thompson
Journal: Genes Dev Date: 1997-11-01 Impact factor: 11.361

6. The TNF receptor family member CD30 is not essential for negative selection.

Authors: A L DeYoung; O Duramad; A Winoto
Journal: J Immunol Date: 2000-12-01 Impact factor: 5.422

7. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease.

Authors: Bruce R Blazar; Robert B Levy; Tak W Mak; Angela Panoskaltsis-Mortari; Hiromi Muta; Monica Jones; Melinda Roskos; Jonathan S Serody; Hideo Yagita; Eckhard R Podack; Patricia A Taylor
Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422

8. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors: C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal: Cell Date: 1993-07-02 Impact factor: 41.582

9. PML-IRIS in a patient treated with brentuximab.

Authors: Gloria von Geldern; Carlos A Pardo; Peter A Calabresi; Scott D Newsome
Journal: Neurology Date: 2012-10-31 Impact factor: 9.910

10. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.

Authors: Xun Sun; Shinichi Somada; Kensuke Shibata; Hiromi Muta; Hisakata Yamada; Hirofumi Yoshihara; Kuniomi Honda; Kazuhiko Nakamura; Ryhoichi Takayanagi; Kenzaburo Tani; Eckhard R Podack; Yasunobu Yoshikai
Journal: Gastroenterology Date: 2007-11-04 Impact factor: 22.682

8 in total

1. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

Authors: Lei Kang; Dawei Jiang; Emily B Ehlerding; Todd E Barnhart; Dalong Ni; Jonathan W Engle; Rongfu Wang; Peng Huang; Xiaojie Xu; Weibo Cai
Journal: Mol Pharm Date: 2018-03-20 Impact factor: 4.939

2. Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Authors: Andreas A Hombach; André Görgens; Markus Chmielewski; Florian Murke; Janine Kimpel; Bernd Giebel; Hinrich Abken
Journal: Mol Ther Date: 2016-04-26 Impact factor: 11.454

3. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Authors: Katharina Blatt; Sabine Cerny-Reiterer; Juliana Schwaab; Karl Sotlar; Gregor Eisenwort; Gabriele Stefanzl; Gregor Hoermann; Matthias Mayerhofer; Mathias Schneeweiss; Sylvia Knapp; Thomas Rülicke; Emir Hadzijusufovic; Karin Bauer; Dubravka Smiljkovic; Michael Willmann; Andreas Reiter; Hans-Peter Horny; Peter Valent
Journal: Blood Date: 2015-10-20 Impact factor: 22.113

4. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.

Authors: Sudhakiranmayi Kuravi; Janice Cheng; Gabrielle Fangman; Kishore Polireddy; Sophia McCormick; Tara L Lin; Anurag K Singh; Sunil Abhyankar; Siddhartha Ganguly; Danny R Welch; Roy A Jensen; Joseph P McGuirk; Ramesh Balusu
Journal: Mol Cancer Res Date: 2021-01-29 Impact factor: 6.333

Review 5. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Authors: Michael Sandherr; Marcus Hentrich; Marie von Lilienfeld-Toal; Gero Massenkeil; Silke Neumann; Olaf Penack; Lena Biehl; Oliver A Cornely
Journal: Ann Hematol Date: 2015-07-21 Impact factor: 3.673